ABCL — AbCellera Biologics Inc.

Summary of AbCellera's Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Total revenue for 2025 was $75 million, up from $29 million in 2024, driven by $27 million from partnered programs and $47 million from licensing and royalty payments, including $36 million from a patent settlement with Bruker.
• Expenses: R&D expenses increased to $187 million, reflecting investments in internal programs. SG&A expenses decreased slightly to $83 million.
• Net Loss: Reported net loss was approximately $146 million, an improvement from a loss of $163 million in the previous year, translating to a loss of $0.49 per share.
• Liquidity: Ended the year with about $700 million in available liquidity, including $560 million in cash and equivalents and $140 million in committed government funding.

2. Strategic Updates and Business Highlights:

• Successfully transitioned to a clinical-stage biotech, achieving all four strategic priorities set for 2025, including the initiation of Phase I trials for two programs and the nomination of two new development candidates (ABCL688 and ABCL386).
• Pipeline now includes four clinical programs, with ABCL635 advancing to a Phase II study and two additional programs in IND-enabling activities.
• Over 20 programs are in discovery, with plans to advance a fifth program into IND-enabling activities in the first half of 2026.

3. Forward Guidance and Outlook:

• Key priorities for 2026 include delivering top-line readouts for ABCL635 (Phase II) and ABCL575 (Phase I), advancing ABCL688 and ABCL386, and adding one new development candidate.
• Anticipated Phase II readout for ABCL635 in Q3 2026, which could significantly influence the company's trajectory, particularly if it demonstrates efficacy comparable to existing treatments.
• Expectation to have five clinical-stage programs by mid-2027 across various indications.

4. Bad News, Challenges, or Points of Concern:

• Risks associated with drug development remain, particularly regarding the efficacy of ABCL635, which may not meet expectations despite encouraging biomarker data.
• Potential delays in progressing to late-stage clinical trials if the Phase II readout is negative.
• Uncertainty regarding the competitive landscape, especially with emerging therapies in the same indications, which could impact the market potential of ABCL575 and other pipeline candidates.

5. Notable Q&A Insights:

• Discussions on ABCL575 highlighted its potential as a combination therapy, with ongoing evaluations of external partnerships to enhance its development.
• Insights into ABCL635 indicated that the Phase I data will be presented alongside the Phase II results, with expectations for a comprehensive update on safety and efficacy.
• The management emphasized their confidence in the OX40 ligand class, despite recent safety concerns raised in the market, maintaining a positive outlook on the drug's potential.

Overall, AbCellera is positioned for significant developments in 2026, with a strong liquidity position and a focus on advancing its clinical pipeline, though it faces inherent risks in drug development and competitive pressures in the biotech landscape.